Cover Image

Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis

Background/Objectives: Implementing model-informed precision dosing (MIPD) strategies guided by population pharmacokinetic/pharmacodynamic (PK/PD) models could enhance the management of inflammatory diseases such as psoriasis. However, the extent of individual experimental data gathered during MIPD...

Full description

Saved in:

Bibliographic Details
Main Authors:	Karine Rodríguez-Fernández (Author), Javier Zarzoso-Foj (Author), Marina Saez-Bello (Author), Almudena Mateu-Puchades (Author), Antonio Martorell-Calatayud (Author), Matilde Merino-Sanjuan (Author), Elena Gras-Colomer (Author), Monica Climente-Martí (Author), Victor Mangas-Sanjuan (Author)
Format:	Book
Published:	MDPI AG, 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
by: Karine Rodríguez-Fernández, et al.
Published: (2022)

Influence of Inter- and Intra-Batch Variability on the Sample Size Required for Demonstration of Equivalent Microstructure of Semisolid Dosage Forms
by: Zhengguo Xu, et al.
Published: (2020)

Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making
by: Javier Reig-López, et al.
Published: (2021)

Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study
by: Andreu Mañez-Asensi, et al.
Published: (2024)

Population Pharmacokinetic-Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats
by: Gloria M. Alfosea-Cuadrado, et al.
Published: (2024)

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
by: Martina Burlando, et al.
Published: (2021)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
by: Nora Koutruba, et al.
Published: (2010)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
by: Martina Burlando, MD, et al.
Published: (2020)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020)

Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment
by: Teresa García-Martínez, et al.
Published: (2022)

[Translated article] Psoriasis and Anti-PD-1 and Anti-PD-L1 Immunotherapy: Three Cases, a Review of the Literature, and a Proposed Management Algorithm
by: E. Sánchez-Martínez, et al.
Published: (2022)

Psoriasis y anti-PD1/anti-PDL1: presentación de tres casos, revisión de la literatura y propuesta de algoritmo de manejo
by: E. Sánchez-Martínez, et al.
Published: (2022)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018)

Ustekinumab: differential use in psoriasis
by: Uhlenhake EE, et al.
Published: (2011)

Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
by: Akihiko Asahina, et al.
Published: (2023)

Ustekinumab
by: Murat Borlu
Published: (2022)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
by: Bayanne Olabi, et al.
Published: (2020)

Erratum: Mangas-Sanjuán, V.; et al. Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence. <i>Pharmaceutics</i> 2019, <i>11</i>, 503
by: Víctor Mangas-Sanjuán, et al.
Published: (2020)

Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence
by: Víctor Mangas-Sanjuán, et al.
Published: (2019)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
by: Hampton P, et al.
Published: (2021)

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
by: Javier Reig-López, et al.
Published: (2020)

Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union
by: Alfredo García-Arieta, et al.
Published: (2023)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
by: Maeve Lynch, MD, MBBChBAO, et al.
Published: (2017)

[Translated article] Erythematous Facial Plaques With an Unfavorable Course
by: C. Tubau, et al.
Published: (2022)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
by: Marina Papoutsaki, et al.
Published: (2009)

Treatment of recalcitrant disseminated ulcerative necrobiosis lipoidica with ustekinumab
by: Patrick McMullan, PhD, et al.
Published: (2023)

Conceptos y aplicaciones de los parámetros farmacocinéticos: Una guía para el salón de clases. | [Concepts and applications of pharmacokinetic parameters: A guide for the classroom]
by: Jorge Duconge-Soler, et al.
Published: (2023)

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
by: Aymara Sancho-Araiz, et al.
Published: (2021)

Ustekinumab in the Treatment of Generalized Pustular Psoriasis in a Pregnant Patient
by: Wu H, et al.
Published: (2024)

Editorial: Innovative pharmacometric approaches to inform drug development and clinical use
by: Maria Garcia-Cremades, et al.
Published: (2023)

Late reaction to ustekinumab infusion
by: Marina Resener Morais, et al.
Published: (2013)

Paradoxical granulomatous reaction to ustekinumab
by: Chinemelum Obijiofor, et al.
Published: (2024)

Efficacy and safety of ustekinumab in adolescents
by: Kellen R, et al.
Published: (2016)

Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study
by: Lu W, et al.
Published: (2024)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
by: Aline Lissa Okita, et al.
Published: (2020)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
by: Grace C. Brummer, BS, et al.
Published: (2017)

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology
by: Raquel Bissacotti Steglich, et al.
Published: (2014)

Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience
by: Melis Gönülal, et al.
Published: (2023)

Ustekinumab for the treatment of psoriatic arthritis: an update
by: Davari P, et al.
Published: (2014)

Interstitial Granulomatous Drug Reaction to Ustekinumab
by: A. Walker, et al.
Published: (2022)